Article
Continuous flow peritoneal dialysis: principles and applications.
Division of Nephrology and Hypertension, Beth Israel Medical Center, New York, 10003, USA.
Seminars in Dialysis (impact factor:
2.27).
16(4):335-40.
pp.335-40
Source: PubMed
-
Citations (0)
- Cited In (2)
-
Article: [Peritoneal dialysis in patients with acute renal failure].
[show abstract] [hide abstract]
ABSTRACT: The management of patients with acute renal failure (ARF) is very complex and requires meticulous attention to fluid, acid-base and electrolyte balance as well as the removal of uraemic toxins. Peritoneal dialysis (PD) is an important option for treatment of selected patients with ARF, particularly those who are haemodynamically compromised or have coagulation abnormalities. Due to continuous therapy, its efficacy is the same as on haemodialysis, even better. Advantages of PD in ARF therapy: it is widely available and easy to perform; insertion of PD catheter is relatively easy, PD does not require special staff or expensive equipment, arterial or venous puncture and anticoagulation; dosing is easy; there is no interaction between blood and dialyser and there are no episodes of hypotension like in haemodialysis (HD) patients; acid-base and electrolyte imbalance may be easily and gradually corrected, large amounts of fluid can be removed in haemodynamically unstable patients, which allows parenteral nutrition. PD is less efficient than HD in therapy of acute complications (pulmonary oedema, intoxication or hyperkaliaemia) and is not the therapy of choice in patients with extreme catabolism who require daily HD or some other kind of continuous renal replacement therapy. The absolute indication for acute PD is the need for dialysis and inability to perform any other renal replacement technique. Relative indications for acute PD in adults are the following: haemodynamically unstable patients, the presence of bleeding or haemorrhagic conditions, difficulty in obtaining vascular approach, removal of high molecular weight toxins, heart failure refractory to medical treatment. Absolute contraindications for PD are the following: recent abdominal or cardiothoracic surgery, diaphragmatic peritoneal-pleural connections, faecal or fungal peritonitis. Other contraindications are relative. Accordingly, acute PD is the mode of therapy in some specific patients with ABI, especially patients in intensive care units. Survival of ARF patients is similar in PD and HD patients, so acute PD is very important in their therapy.Srpski arhiv za celokupno lekarstvo 135(7-8):478-85. · 0.19 Impact Factor -
Article: Impact of glucose in peritoneal dialysis: saint or sinner?
[show abstract] [hide abstract]
ABSTRACT: Peritoneal dialysis (PD) solutions using glucose as osmotic agent have been used for more than two decades as effective treatment for patients with end-stage renal disease. Although alternative osmotic agents such as amino acids and macromolecular solutions, including polypeptides and glucose polymers, are now available, glucose is still the most widely used osmotic agent in PD. It has been shown to be safe, effective, readily metabolized, and inexpensive. On the other hand, it is widely assumed that exposure of the peritoneal membrane to high glucose concentrations contributes to both structural and functional changes in the dialyzed peritoneal membrane. As in diabetes, glucose, either directly or indirectly through the generation of glucose degradation products or the formation of advanced glycation end products, may contribute to peritoneal membrane failure. Although efforts to reduce glucose toxicity have been made for years, only a few suggestions, such as dual-bag systems with bicarbonate as buffer system, have found broader acceptance. Recently, some interesting new approaches to the problem of glucose-related toxicity have been made, but further investigations will be necessary before they can be used clinically. This review will focus on adverse effects of glucose in PD solutions and summarize different aspects of glucotoxicity and potential therapeutic interventions.Peritoneal dialysis international: journal of the International Society for Peritoneal Dialysis 25(5):415-25. · 2.10 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
acute renal failure
Continuous flow peritoneal dialysis
continuous movement
conventional hemodialysis
dialysate flow
External regeneration
fixed intraperitoneal volume
home dialysis
intensive care unit
peritoneal cavity
peritoneal dialysis
peritoneal mass transfer coefficient
Potential applications
renal replacement therapy
small solute clearances
sorbent technology mitigates
sterile dialysate
sterile fluid
technique feasible
times greater